Patent · US Active

1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease

US7638539B2 · kind B2 · utility

1Cited by

2References

2Claims

0Family size

Assignees

Aventis Pharmaceuticals Inc. · US
Sanofi-Aventis Deutschland GMBH · DE

Inventors

Daniel McGarry · King of Prussia, US
Jochen Goerlitzer · Frankfurt am Main, DE
Stefanie Keil · Frankfurt am Main, DE
Karen Chandross · Somerville, US
Jean Merrill · Morristown, US
Wolfgang Wendler · Bad Camberg, DE

Key dates

Filing date	Sep 27, 2006
Grant date	Dec 29, 2009
Priority date	—
Expiry date	Sep 27, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D277/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.